Article: Celgene Corporation Reports Record Third Quarter Revenue and Operating Profits.

Product Sales Drive Record Third Quarter Revenue and Profits:

* Record Net Product Sales of $223.1 Million

- REVLIMID Achieved $101.3 Million in Net Product Sales

- THALOMID Net Product Sales Totaled $108.4 Million

* Record Adjusted Net Income of $59.4 Million with Adjusted Diluted Earnings Per Share of $0.15

Financial Highlights of Third Quarter Performance Year-Over-Year:

* Total Revenue Increased 89.1% to a Record $244.8 Million

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!